接受丁丙诺啡治疗阿片类物质使用障碍的孕妇早产危险因素
本回顾性队列研究纳入2013年7月1日至2018年6月30日期间在某三级学术医疗中心分娩、因阿片类物质使用障碍接受丁丙诺啡治疗且至少3次就诊的507例单胎孕妇,早产率为22.7%(115/507)。有早产史者本次妊娠早产可能性更高(73% vs 16%,P<.01),未发现内科或感染性合并症及额外违禁药物使用增加早产风险。
要点
- 该队列早产率为22.7%(115/507),高于全国平均水平但低于使用美沙酮者的已报告早产率。
- 本次妊娠早产者较足月分娩者更常有早产史(73% vs 16%,P<.01)。
- 未发现内科或感染性合并症或任何特定额外违禁药物增加早产风险。
核心结论
- 使用丁丙诺啡治疗阿片类物质使用障碍者的早产率为22.7%,高于全国平均水平但低于使用美沙酮治疗者的已报告早产率。
- 未发现内科或感染性合并症或额外违禁物质使用增加早产风险。
研究设计与样本
- 回顾性队列研究,纳入2013年7月1日至2018年6月30日期间在某三级学术医疗中心分娩、因阿片类物质使用障碍接受丁丙诺啡治疗的单胎孕妇,要求至少3次就诊于该中心联合门诊,共507例。
- 按分娩孕周分为早产组(<37周)和足月组(≥37周),评估内科与感染性合并症及违禁多物质使用等潜在早产危险因素。
主要发现
- 该队列总体早产率为22.7%(115/507)。
- 研究期间总体早产率及提供者发起的早产率呈下降趋势,但无统计学意义。
- 两组在<34周自发性早产率、烟草或酒精使用、产前检查次数及开始产前保健孕周方面均无差异。
- 本次妊娠早产者较足月分娩者更常有早产史(73% vs 16%;P<.01)。
- 在确认使用丁丙诺啡基础上额外使用0、1、2、3种及以上违禁补充物质者的早产率分别为27.4%(参考组)、18.0%(P=.09)、18.1%(P=.44)、15.8%(P=.77)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid use disorder (OUD) has dramatically increased over the last few decades, with 11.5 million American misusing opioids in 2016. Untreated OUD in pregnancy is associated with unique adverse obstetric and perinatal outcomes including insufficient prenatal care, preterm birth (PTB), fetal growth restriction, fetal demise, and placental abruption . The mainstay treatment for OUD management in pregnancy is medication for opioid use disorder (MOUD) including methadone or buprenorphine. The association of PTB and opioid use in pregnancy has been described for over 50 years, and efforts to significantly eliminate this risk are challenged by the many confounding risks described above. When comparing rates of PTB in individuals with OUD on methadone vs buprenorphine. Buprenorphine has been associated with overall lower PTB than Methadone by almost 50 %. OBJECTIVE: Pregnancies complicated by opioid use disorder are at an increased risk for preterm birth, defined as delivery <37 weeks' gestation. Limited literature is available on the prevalence and risk factors for preterm birth in pregnancies complicated by opioid use disorder maintained on buprenorphine. Therefore, we sought to determine the rate of preterm birth and risk factors for preterm birth in this population. STUDY DESIGN: We performed a retrospective cohort study of pregnant individuals with singleton gestations receiving buprenorphine for opioid use disorder, who delivered at a tertiary academic medical center between July 1, 2013 and June 30, 2018. Individuals who had at least 3 visits to our colocated clinic were included in the analysis. Patients were divided into 2 groups: the preterm group for patients who delivered at <37 weeks of gestation and the term group for those who delivered at ≥37 weeks of gestation. We defined "supplements to buprenorphine" to include any illicit drugs found on antepartum urine toxicology. Variables evaluated as potential risk factors for preterm birth included medical and infectious comorbidities and illicit polysubstance use. RESULTS: The overall preterm birth rate in this cohort was 22.7% (115/507). There was a nonsignificant trend toward decrease in overall preterm birth and provider-initiated preterm birth rate over the study period. No differences were found between the groups in spontaneous preterm birth rate at <34 weeks of gestation. There were no differences between the groups in the use of tobacco or alcohol, number of prenatal visits, or gestational age when prenatal care started. Individuals with preterm birth in the index pregnancy were more likely to have a history of preterm birth than individuals with term delivery (73% vs 16%; P<.01). No medical or infectious comorbidity or any specific supplement increased the risk of preterm birth. Among individuals using 0, 1, 2, or 3 or more illicit supplements in addition to confirmed buprenorphine for opioid use disorder, the preterm birth rate was 27.4% (reference), 18.0% (P=.09), 18.1% (P=.44), and 15.8% (P=.77), respectively. CONCLUSION: The preterm birth rate among individuals using buprenorphine for opioid use disorder (22.7%) is higher than the national average but lower than the reported preterm birth rate in individuals using methadone for the treatment of opioid use disorder. No medical or infectious comorbidity or use of additional illicit substances increased the risk of preterm birth.
引用
- Abdelwahab M, Petrich M, Wang H, et al. Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder. Am J Obstet Gynecol MFM. 2022. PMID: 35123110. doi:10.1016/j.ajogmf.2022.100582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。